Skip to main
BCTX
BCTX logo

BCTX Stock Forecast & Price Target

BCTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BriaCell Therapeutics Corp has demonstrated a strong commitment to advancing its immunotherapy programs, highlighted by the recent award of a non-dilutive $2 million grant from the US National Cancer Institute (NCI) to enhance the manufacturing of Bria-PROS+ and support its Phase 1/2a development for metastatic prostate cancer. This financial backing not only reflects confidence in BriaCell's innovative approaches but also positions the company to expedite the clinical development of its personalized off-the-shelf therapeutic platform, Bria-OTS+. Furthermore, BriaCell's ongoing focus on developing targeted immunotherapies for breast cancer, combined with its strategic collaborations for combination therapies, underpins a robust outlook for the company’s growth potential in the competitive biotechnology landscape.

Bears say

BriaCell Therapeutics faces significant risks that contribute to a negative outlook, including the potential for adverse safety signals from its clinical and preclinical programs and challenges related to achieving expected efficacy in trials. The company is projected to require approximately $120 million in additional financing by 2037, with further capital needs anticipated in fiscal year 2026, adding pressure on its financial stability. Additionally, the company faces increasing commercial competition and regulatory uncertainties that could hinder its product development and market entry.

BCTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BriaCell Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BriaCell Therapeutics (BCTX) Forecast

Analysts have given BCTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, BCTX has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BriaCell Therapeutics (BCTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.